Tournigand et al (2004)r:
After a median follow up of 43.9 months, median PFS after first line therapy was 8.5 months for arm A and 8.0 months for arm B (p=0.26).
Following second line therapy, the median second PFS from randomisation was 14.2 months in arm A versus 10.9 months in arm B. (p=0.64).
The median overall survival (OS) was 21.5 months for arm A versus 20.6 months for arm B (p=0.99).
After first line therapy, the response rates (RRs) were 56% with FOLFIRI versus 54% with FOLFOX6 (p=not significant) and after second line therapy, RRs were 15% with FOLFOX 6 versus 4% with FOLFIRI.
|Progression free survival (after first line therapy)
|| 8.5 months
|Second progression free survival (from randomisation)
|| 20.6 months
arm A: FOLFIRI followed by FOLFOX6
arm B: FOLFOX6 followed by FOLFIRI
Kaplan-meier curves of Progression-free survivalr
© Journal of Clinical Oncology 2004
Colucci et al (2005)r:
After a median follow up of 31 months, the overall response rates (ORR) were 31% in arm A and 34% in arm B (p=0.6) according to intent to treat analysis. Median time to progression, duration of response and overall survival were not statistically different between both arms.
|Time to progression